• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体:结构、调控及其在恶性肿瘤中的潜在作用

The EGF receptor: structure, regulation and potential role in malignancy.

作者信息

Thompson D M, Gill G N

机构信息

Department of Medicine, University of California, San Diego, School of Medicine, La Jolla 92093.

出版信息

Cancer Surv. 1985;4(4):767-88.

PMID:2824044
Abstract

Retroviral onc genes are derived from cellular proto-oncogenes that may function in normal cellular growth control. The epidermal growth factor (EGF) receptor is the proto-oncogene of erbB; both possess intrinsic protein tyrosine kinase activity, a property shared by several retroviral onc genes. The EGF receptor is a transmembrane glycoprotein with an external EGF binding domain and a cytoplasmic region that is homologous with other tyrosine kinases. erbB lacks the EGF binding and carboxyl terminal regions, which are thought to be important in regulation. The EGF receptor is regulated by several mechanisms: stimulation by ligand binding and self-phosphorylation, inhibition by heterologous phosphorylation and downregulation by ligand. EGF binding stimulates several early events, including phosphatidylinositol (PI) turnover in A431 cells. A PI kinase activity copurifies with the EGF receptor and some other tyrosine kinases, but this is a contaminant as it can be separated from the EGF receptor. Although the role of proto-onc genes in human malignancy is incompletely defined, increased numbers of EGF receptors are present in several types of human tumours. Overexpression of EGF receptors, as occurs in human epidermoid carcinoma A431 cells, can augment cell growth because of increased formation of active ligand:receptor complexes. Gene amplification is the mechanism underlying overexpression of EGF receptors in A431 cells and in some glioblastoma multiforme tumours.

摘要

逆转录病毒致癌基因源自可能在正常细胞生长控制中发挥作用的细胞原癌基因。表皮生长因子(EGF)受体是erbB的原癌基因;两者都具有内在的蛋白酪氨酸激酶活性,这是几种逆转录病毒致癌基因共有的特性。EGF受体是一种跨膜糖蛋白,具有外部EGF结合结构域和与其他酪氨酸激酶同源的细胞质区域。erbB缺乏EGF结合区和羧基末端区域,这些区域被认为在调节中很重要。EGF受体受多种机制调节:通过配体结合和自身磷酸化进行刺激,通过异源磷酸化进行抑制,以及通过配体进行下调。EGF结合刺激多种早期事件,包括A431细胞中的磷脂酰肌醇(PI)周转。一种PI激酶活性与EGF受体和其他一些酪氨酸激酶共纯化,但这是一种污染物,因为它可以与EGF受体分离。尽管原癌基因在人类恶性肿瘤中的作用尚未完全明确,但在几种类型的人类肿瘤中存在数量增加的EGF受体。如在人类表皮样癌A431细胞中发生的那样,EGF受体的过表达可由于活性配体:受体复合物形成增加而增强细胞生长。基因扩增是A431细胞和一些多形性胶质母细胞瘤肿瘤中EGF受体过表达的潜在机制。

相似文献

1
The EGF receptor: structure, regulation and potential role in malignancy.表皮生长因子受体:结构、调控及其在恶性肿瘤中的潜在作用
Cancer Surv. 1985;4(4):767-88.
2
The erbB gene and the EGF receptor.erbB基因与表皮生长因子受体
Cancer Surv. 1986;5(2):199-219.
3
Regulation of the epidermal growth factor receptor by phosphorylation.通过磷酸化对表皮生长因子受体的调控。
J Cell Biochem. 1985;29(3):195-208. doi: 10.1002/jcb.240290304.
4
The role of the neu oncogene product in cell transformation and normal development.神经癌基因产物在细胞转化和正常发育中的作用。
Princess Takamatsu Symp. 1988;19:45-57.
5
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.在有丝分裂期间,神经分化因子/神经调节蛋白可有效诱导p185erbB - 2和erbB - 3募集磷脂酰肌醇3 -激酶,并且在具有c - erbB - 2基因扩增的不依赖生长因子的乳腺癌细胞中,该过程持续增强。
Cell Growth Differ. 1996 May;7(5):551-61.
6
Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.表皮生长因子(EGF)受体即时及延迟作用中对内在蛋白酪氨酸激酶的需求
Nature. 1987;328(6133):820-3. doi: 10.1038/328820a0.
7
Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes.某些受体型酪氨酸激酶癌基因的结构与激活分析。
Princess Takamatsu Symp. 1986;17:195-202.
8
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.由人类HER-2基因介导的转化,独立于表皮生长因子受体。
Oncogene. 1992 Sep;7(9):1859-66.
9
Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.表皮生长因子受体和erbB - 2受体酪氨酸激酶活性的差异热应激稳定性
J Cell Physiol. 1993 Nov;157(2):237-42. doi: 10.1002/jcp.1041570205.
10
Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.在具有c-erbB-2基因扩增且酪氨酸磷酸化的p185erbB-2水平逐渐升高的人乳腺癌细胞中胰岛素样生长因子和表皮生长因子非依赖性
Mol Carcinog. 1996 Mar;15(3):227-38. doi: 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E.

引用本文的文献

1
EGFR mutations and abnormal trafficking in cancers.EGFR 突变与癌症中的异常转运。
Mol Biol Rep. 2024 Aug 21;51(1):924. doi: 10.1007/s11033-024-09865-z.
2
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
3
Crosstalk of MAP3K1 and EGFR signaling mediates gene-environment interactions that block developmental tissue closure.MAP3K1 和 EGFR 信号的串扰介导了阻止发育组织闭合的基因-环境相互作用。
J Biol Chem. 2024 Jul;300(7):107486. doi: 10.1016/j.jbc.2024.107486. Epub 2024 Jun 18.
4
Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023.表皮生长因子受体相关的皮肤毒性:一项2013年至2023年的综合药物警戒研究
Front Med (Lausanne). 2024 Jan 24;10:1283807. doi: 10.3389/fmed.2023.1283807. eCollection 2023.
5
Enzyme Inhibitors from Gorgonians and Soft Corals.海葵和软珊瑚中的酶抑制剂。
Mar Drugs. 2023 Jan 31;21(2):104. doi: 10.3390/md21020104.
6
Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.EGFR 拮抗型 EgB4 纳米抗体的非抑制机制的结构见解。
BMC Mol Cell Biol. 2022 Mar 1;23(1):12. doi: 10.1186/s12860-022-00412-x.
7
Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer.表皮生长因子受体家族及其在胃癌中的作用。
Front Oncol. 2019 Nov 26;9:1308. doi: 10.3389/fonc.2019.01308. eCollection 2019.
8
Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in activating mutation-positive advanced non-small-cell lung cancer.阿法替尼对激活突变阳性的晚期非小细胞肺癌进行不可逆的表皮生长因子受体酪氨酸激酶抑制。
Curr Oncol. 2018 Jun;25(Suppl 1):S9-S17. doi: 10.3747/co.25.3732. Epub 2018 Jun 13.
9
Established, emerging and elusive molecular targets in the treatment of lung cancer.肺癌治疗中的既定、新兴和难以捉摸的分子靶点。
J Pathol. 2018 Apr;244(5):565-577. doi: 10.1002/path.5038. Epub 2018 Feb 14.
10
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.消化系统癌症中的HER2异常与异质性:对病理学家和胃肠病学家的启示
World J Gastroenterol. 2016 Sep 21;22(35):7926-37. doi: 10.3748/wjg.v22.i35.7926.